Lv1
30 积分 2023-11-25 加入
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
15小时前
待确认
1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
17天前
已完结
[Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)]
20天前
已完结
[Interpretation of 2023 European Society of Cardiology (ESC) Guidelines for the management of cardiovascular disease in patients with diabetes]
20天前
已完结
Role of IL8 in myeloid malignancies
21天前
已完结
[Research Progress of Cytokines in the Prognosis of Acute Myeloid Leukemia --Review]
22天前
已完结
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
27天前
已关闭
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)
28天前
已关闭
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
1个月前
已完结
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
1个月前
已关闭
皖公网安备34019202002308
